Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Transthyretin amyloid cardiomyopathy (ATTR-CM) results in a restrictive cardiomyopathy
caused by extracellular deposition of transthyretin, normally involved in the transportation of …

Background Transthyretin amyloid (ATTR) cardiomyopathy is a progressive and fatal
disease caused by misfolded transthyretin. Despite advances in slowing disease …

Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …

Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …

Cardiovascular (CV) imaging is an important tool in baseline risk assessment and detection
of CV disease in oncology patients receiving cardiotoxic cancer therapies. This position …

Transthyretin amyloid cardiomyopathy (ATTR-CM) is an under-recognized cause of heart
failure (HF) in older adults, resulting from myocardial deposition of misfolded transthyretin …

Cardiomyopathy is a manifestation of transthyretin amyloidosis (ATTR), which is an
underrecognized systemic disease whereby the transthyretin protein misfolds to form fibrils …

Sharmila Dorbala, MD, MPH, FASNC, Chair*; Yukio Ando, MD, PhD†; Sabahat Bokhari,
MD‡; Angela Dispenzieri, MD § ; Rodney H. Falk, MD*; Victor A. Ferrari, MD∥; Marianna …

Transthyretin cardiac amyloidosis (ATTR-CA) is an increasingly recognized cause of heart
failure (HF) and mortality worldwide. Advances in non-invasive diagnosis, coupled with the …